Use of a molecular bacterial load assay to distinguish between active TB and post-TB lung disease
MetadataShow full item record
Altmetrics Handle Statistics
Altmetrics DOI Statistics
Mbelele , P M , Sabiiti , W , Heysell , S K , Sauli , E , Mpolya , E A , Mfinanga , S , Gillespie , S H , Addo , K K , Kibiki , G , Sloan , D J & Mpagama , S G 2022 , ' Use of a molecular bacterial load assay to distinguish between active TB and post-TB lung disease ' , International Journal of Tuberculosis and Lung Disease , vol. 26 , no. 3 , pp. 276-278 . https://doi.org/10.5588/ijtld.21.0459
International Journal of Tuberculosis and Lung Disease
Copyright © 2022 The Author(s). Original content from this work may be used under the terms of the Creative Commons Attribution International 4.0 licence. Any further distribution of this work must maintain attribution to the author(s) and the title of the work, journal citation and DOI.
DescriptionAuthors acknowledge financial support from the EDCTP2 programme supported by the European Union project (grant #: TMA2016SF-1463-REMODELTZ) and DELTAS Africa Initiative (Afrique One-ASPIRE /DEL-15-008). The Afrique One-ASPIRE is funded by a consortium of donors including the African Academy of Sciences, Alliance for Accelerating Excellence in Science in Africa, the New Partnership for Africa's Development Planning and Coordinating Agency, the Wellcome Trust (107753/A/15/Z), and the UK Government. PMM, SKH and SGM were also supported by NIH U01AI115594.
Items in the St Andrews Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.
Showing items related by title, author, creator and subject.
A review of clinical trial designs used to detect a disease-modifying effect of drug therapy in Alzheimer’s disease and Parkinson’s disease McGhee, David J. M.; Ritchie, Craig W.; Zajicek, John Peter; Counsell, Carl E. (2016-06-16) - Journal articleBackground. Disease-modification clinical trials in neurodegenerative disorders have struggled to separate symptomatic effects of putative agents from disease-modification. In response, a variety of clinical trial designs ...
Petrie, John R; Rossing, Peter R; Campbell, Ian W (2020-02-18) - Journal itemThe guidance issued to the pharmaceutical industry by the US Food and Drug Administration in 2008 has led to the publication of a series of randomised, controlled cardiovascular outcomes trials with newer therapeutic classes ...
Minskaia, Ekaterina; Ryan, Martin D. (2013-04) - Journal articleMany biomedical applications absolutely require, or are substantially enhanced by, coexpression of multiple proteins from a single vector. Foot-and-mouth disease virus 2A (F2A) and “2A-like” sequences (e.g., Thosea asigna ...